Krankenhaushygiene up2date, Table of Contents Krankenhaushygiene up2date 2013; 08(02): 113-125DOI: 10.1055/s-0033-1344340 Antibiotikaanwendung © Georg Thieme Verlag KG Stuttgart · New York Tuberkulose-Screening und präventive Chemotherapie bei Beschäftigten im Gesundheitswesen Roland Diel , Albert Nienhaus Recommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2011. Berlin: RKI; 2013 2 American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: 221-S247 3 Schaberg T, Bauer T, Castell S et al. [Recommendations for therapy, chemoprevention, and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie 2012; 66: 133-171 4 Diel R et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen. Pneumologie 2009; 63: 329-334 5 Diel R, Goletti D, Ferrara G et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99 6 Diel R et al. Neue Empfehlungen des Deutschen Zentralkomitees (DZK) für die Umgebungsuntersuchungen bei Tuberkulose. Pneumologie 2011; 65: 359-378 7 Diel R, Seidler A, Nienhaus A et al. Occupational risk of tuberculosis transmission in a low incidence area. Respir Res 2005; 6: 35-45 8 Nienhaus A, Brandenburg S, Teschler H Hrsg. Tuberkulose als Berufskrankheit – ein Leitfaden zur Begutachtung und Vorsorge. 3.. Aufl. Heidelberg: Ecomed; 2012 9 Torres CJ, Sa R, Cardoso MJ et al. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay. Eur Respir J 2009; 34: 1423-1428 10 Schablon A, Harling M, Diel R et al. Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicentre prevalence study. BMC Infect Dis 2010; 10: 107 11 Schablon A, Diel R, Diner G et al. Specificity of a whole blood IGRA in German nursing students. BMC Infect Dis 2011; 11: 245 12 Diel R, Loddenkemper R, Niemann S et al. Negative and positive predictive value of a whole-blood IGRA for developing active TB – an update. Am J Respir Crit Care Med 2011; 183: 88-95 13 Haldar P, Thuraisingam H, Patel H et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013; 68: 240-246 14 Nienhaus A, Costa JT. Screening for tuberculosis and the use of a borderlin zone for the interpretation of the interferon-γ release assay (IGRA) in Portuguese healthcare workers. J Occup Med Toxicol 2013; 28: 1 15 Diel R, Loddenkemper R, Meywald-Walter K et al. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot. TB test in contact investigations for tuberculosis. Chest 2009; 135: 1010-1018 16 Ziegler R, Just HM, Castell S et al. Infektionsprävention bei Tuberkulose. Empfehlungen des DZK. Gesundheitswesen 2012; 74: 337-350 17 Smieja MJ, Marchetti CA, Cook DJ et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999; 1 CD001363 18 Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin- a meta-analysis. Chest 1991; 99: 465-471 19 Thompson NJ. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564 20 Kopanoff DE, Snider Jr DE, Caras GJ. Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001 21 Diel R, Nienhaus A. Prevention of TB in areas of low incidence. European Respiratory Society Monograph 2012; 58 : 72-83 22 Sterling TR, Villarino ME, Borisov AS et al. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N Engl J Med 2011; 365: 2155-2166 23 Martinson NA, Barnes GL, Moulton LH et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20 24 Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR 2011; 60: 1650-1653 25 Holland DP, Sanders GD, Hamilton CD et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179: 1055-1060
